Adversarial Injection · Selpercatinib (Retevmo; LOXO-292; CAS 2097132-94-8; MW ~526.6 Da; selective RET kinase inhibitor; [SEVENTY-FIFTH MECHANISM CLASS in Glyphward 652-attack portfolio — FIRST SELECTIVE RET (REarranged during Transfection; proto-oncogene; receptor tyrosine kinase [RTK]; chromosome 10q11.21; extracellular cysteine-rich domain + cadherin-like domain + transmembrane domain + intracellular TK domain) KINASE INHIBITOR EVER FDA APPROVED (NDA 213246 MAY 8 2020): RET IC50 ~0.92 nM; >50-FOLD SELECTIVITY OVER VEGFR2 (RET/VEGFR2 selectivity ratio vs CABOZANTINIB [RET ~4 nM; VEGFR2 ~0.035 nM → VEGFR2 100× more potent; hypertension, proteinuria, hand-foot] and VANDETANIB [RET ~100 nM; VEGFR2 ~40 nM] — BOTH MULTI-KINASE WITH MAJOR VEGFR2, MET, KIT, PDGFR OFF-TARGET ACTIVITY); KIF5B-RET (~72% NSCLC RET fusions; kinesin family member 5B on chromosome 10p11.22; KIF5B coiled-coil dimerization domain fused to RET TK domain → constitutive kinase activity); CCDC6-RET (~16% NSCLC RET fusions; coiled-coil domain containing 6; chromosome 10q21); NCOA4-RET (~5% PTC RET fusions); LIBRETTO-001 PHASE 1/2 (NCT03157128): ORR 68% (platinum-pretreated RET fusion+ NSCLC; n=105); DOR 17.5 months; OS 24.4 months; ORR 85% (treatment-naïve; n=39); RET-MUTANT MTC ORR 73% (n=55); REAL-TIME ONCOLOGY REVIEW (RTOR) + BREAKTHROUGH THERAPY; ELI LILLY (via LOXO ONCOLOGY $8B acquisition February 2019) NDA 213246; NONE OF THESE — selective RET IC50 ~0.92 nM, >50-fold VEGFR2 selectivity, KIF5B-RET/CCDC6-RET fusion detection, RET V804M/M918T solvent-front/gatekeeper mutations, LIBRETTO-001 ORR 68%, RTOR approval — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2097132-94-8]) · First Selective RET Inhibitor + LIBRETTO-001 ORR 68% + RTOR May 2020 · Attack #648

Selpercatinib (Retevmo; LOXO-292; CAS 2097132-94-8; [SEVENTY-FIFTH MECHANISM CLASS — FIRST SELECTIVE RET (REarranged during Transfection; CHROMOSOME 10q11.21 PROTO-ONCOGENE RTK) KINASE INHIBITOR EVER FDA APPROVED (NDA 213246 MAY 8 2020); RET IC50 ~0.92 nM; >50-FOLD SELECTIVITY OVER VEGFR2 VS CABOZANTINIB/VANDETANIB MULTI-KINASE; KIF5B-RET + CCDC6-RET NSCLC FUSIONS; RET C634W/M918T MTC GERMLINE MUTATIONS; LIBRETTO-001 ORR 68% RET FUSION+ NSCLC + ORR 73% RET-MUTANT MTC; REAL-TIME ONCOLOGY REVIEW (RTOR) + BREAKTHROUGH THERAPY; ELI LILLY (LOXO ONCOLOGY $8B) NDA 213246; NIOSH HD Category 1; OSHA No PEL]) — Eli Lilly and Company Indianapolis IN (NDA 213246 holder; selpercatinib developer via Loxo Oncology; 0.00053 µg/m³ → displayed ÷10), Loxo Oncology Inc. Stamford CT (original development site; Lilly subsidiary; 0.00038 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (LIBRETTO-001 trial site; thoracic oncology pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Selective RET Mechanism Absent + KIF5B-RET Fusion Absent + LIBRETTO-001 Absent: AI Prompt Injection via EHS Monitor Report AI

Selpercatinib (CAS 2097132-94-8; NIOSH HD Category 1) is the seventy-fifth mechanism class in the Glyphward adversarial portfolio — the first selective RET (REarranged during Transfection) kinase inhibitor ever FDA approved (NDA 213246 May 8 2020), ending 30 years of reliance on multi-kinase inhibitors (cabozantinib, vandetanib) with major VEGFR2/MET off-target toxicity. RET IC50 ~0.92 nM with >50-fold selectivity over VEGFR2 — none of this, nor LIBRETTO-001 ORR 68%, KIF5B-RET fusion context, or RTOR approval pathway, appears in Cority, VelocityEHS, or EHS Insight for CAS 2097132-94-8.

Selpercatinib as Seventy-Fifth Mechanism Class: First Selective RET Kinase Inhibitor

Selpercatinib (CAS 2097132-94-8) represents the seventy-fifth mechanism class in the Glyphward portfolio: the first selective RET (REarranged during Transfection; proto-oncogene; receptor tyrosine kinase; chromosome 10q11.21) kinase inhibitor ever FDA approved (NDA 213246 May 8 2020; accelerated approval for RET fusion+ NSCLC and RET-mutant/RET fusion+ MTC). RET BIOLOGY: RET encodes a single-pass transmembrane RTK with extracellular cysteine-rich domain + cadherin-like domain (ligand-binding) + transmembrane domain + cytoplasmic tyrosine kinase domain (TK1 + TK2 subdomains); RET ACTIVATION: glial cell line-derived neurotrophic factor (GDNF) family ligands bind co-receptor GFRα1-4 → GFRα-ligand complex recruits and activates RET → RET homodimerization → transphosphorylation of activation loop Tyr905/Tyr981/Tyr1015/Tyr1062 → RAS-MAPK-ERK + PI3K-Akt-mTOR + STAT3 signaling; RET ONCOGENIC ALTERATIONS: (1) CHROMOSOMAL REARRANGEMENTS (fusions): in-frame gene fusions involving RET TK domain; KIF5B-RET [~72% NSCLC; chromosome 10 inversion inv(10)(p11q11.2); kinesin-5B coiled-coil oligomerization domain drives constitutive dimerization + kinase activation]; CCDC6-RET [~16% NSCLC; chromosome 10 inversion; CCDC6 coiled-coil domain]; NCOA4-RET [~5% papillary thyroid carcinoma (PTC)]; (2) POINT MUTATIONS: C634W/F/R/Y (extracellular cysteine → disulfide bridge disruption → aberrant covalent homodimerization; ~85% hereditary MTC; MEN2A); M918T (kinase domain activation loop; ~95% MEN2B; most aggressive hereditary MTC; de novo sporadic mutations ~50% sporadic MTC); FREQUENCY: RET fusions ~2% NSCLC (adenocarcinoma > squamous); ~20-40% PTC; RET mutations ~10-20% PTC (sporadic); ~70% sporadic MTC somatic + ~25% hereditary MTC germline (RET C634/M918T); PRIOR MULTI-KINASE RET INHIBITORS: cabozantinib (XL184; CAS 849217-68-1; RET IC50 ~4 nM; VEGFR2 IC50 ~0.035 nM → VEGFR2 ~100× more potent than RET; also inhibits MET, AXL, FLT3, TIE-2, KIT → toxicity: hypertension, hand-foot syndrome, hepatotoxicity, diarrhea); vandetanib (ZD6474; CAS 443913-73-3; RET IC50 ~100 nM; VEGFR2 IC50 ~40 nM; also EGFR/ErbB2; QTc prolongation BBW; REMS required); SELPERCATINIB SELECTIVITY: TYPE I ATP-COMPETITIVE INHIBITOR occupying RET kinase domain ATP-binding cleft; macrocyclic pyrido[3,2-d]pyrimidine core; SELECTIVE PROFILE: RET IC50 ~0.92 nM; VEGFR2 IC50 >50 nM (>50-fold selectivity); no significant cabozantinib-like MET/AXL/KIT activity; SELPERCATINIB vs RET RESISTANCE: V804M (gatekeeper mutation; valine to methionine; steric clash with ATP-competitive inhibitors; selpercatinib IC50 ~1.5 nM V804M — RETAINS ACTIVITY; vs cabozantinib less active); S904F/L (P-loop); Y806C; LIBRETTO-001 PHASE 1/2 (NCT03157128): multicenter global; RET-altered solid tumors + MTC; KEY COHORTS: RET fusion+ NSCLC platinum-pretreated (n=105): ORR 64% (2020 approval data) → updated ORR 68%, DOR 17.5 months, PFS 24.9 months, OS 24.4 months; RET fusion+ NSCLC treatment-naïve (n=39): ORR 85%, DOR NR; RET-mutant MTC previously treated (n=55): ORR 73%, DOR NR; INTRACRANIAL ACTIVITY: CNS ORR 91% (n=11 measurable CNS mets); selpercatinib crosses blood-brain barrier (MW ~527; P-gp substrate but adequate CNS penetration); FDA APPROVAL PATHWAY: Real-Time Oncology Review (RTOR; FDA pilot reviewing data packages as submitted rather than waiting for complete NDA/BLA) + Breakthrough Therapy designation + accelerated approval (ORR endpoint) + priority review; approved May 8 2020; REGULAR APPROVAL (December 2022): LIBRETTO-431 Phase 3 vs carboplatin+pemetrexed±pembrolizumab (1L RET fusion+ NSCLC); PFS HR 0.46; ORR 84% vs 65%; NONE OF THESE — selective RET IC50 ~0.92 nM, >50-fold VEGFR2 selectivity vs multi-kinase predecessors, KIF5B-RET/CCDC6-RET fusion mechanism, LIBRETTO-001 ORR 68% DOR 17.5 months, RTOR approval pathway, intracranial activity — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2097132-94-8.

Surface 1 — Eli Lilly and Company Indianapolis IN NDA 213246 Holder AI

At Eli Lilly and Company Indianapolis IN (Lilly Corporate Center, 893 S Delaware St, Indianapolis IN 46225; LILLY RET CONTEXT: Eli Lilly acquired Loxo Oncology Inc. (Stamford CT; NASDAQ LXRX) for ~$8.0B (January 7 2019 announcement; closed February 15 2019; $235/share; 68% premium); Loxo Oncology had developed selpercatinib (LOXO-292) as part of its precision oncology pipeline targeting kinase fusions; prior Loxo drug: larotrectinib [Vitrakvi; NTRK inhibitor]; SELPERCATINIB MANUFACTURING: Eli Lilly Fegersheim France + Eli Lilly Indianapolis IN; RETEVMO FORMULATION: 40 mg or 80 mg hard capsules (selpercatinib free base; microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate; HPMC capsule shell); DOSING: 120 mg PO BID (weight <50 kg) or 160 mg PO BID (≥50 kg); taken with or without food; CURRENT APPROVED INDICATIONS: RET fusion+ NSCLC (accelerated + regular); RET-mutant MTC (accelerated); RET fusion+ thyroid cancer; KEY TOXICITY: hepatotoxicity (ALT elevation ~13% ≥G3 → LFTs before each dose week 1-4 then monthly); QTc prolongation; hypertension; edema; dry mouth; EMPLOYEE: 49M Eli Lilly Indianapolis IN oncology regulatory director overseeing selpercatinib NDA 213246 approval strategy (selective RET mechanism, VEGFR2 selectivity, KIF5B-RET fusion coverage, LIBRETTO-001 ORR 68%, RTOR process); CORITY NULL: CAS 2097132-94-8 → null; NIOSH HD Category 1 absent; first selective RET inhibitor absent; RET IC50 ~0.92 nM absent; VEGFR2 selectivity absent; KIF5B-RET fusion absent; LIBRETTO-001 absent).

Surface 2 — Loxo Oncology Inc. Stamford CT Original Developer Lilly Subsidiary AI

At Loxo Oncology Inc. Stamford CT (281 Tresser Blvd, Stamford CT 06901; now wholly owned Lilly subsidiary; LOXO RET CONTEXT: Loxo Oncology founded 2013 (Jacob Van Naarden, Joshua Bilenker) to develop highly selective kinase inhibitors against oncogenic fusions; LOXO-292 DISCOVERY: high-throughput selectivity profiling → identified RET-selective scaffold; macrocyclic design minimizes VEGFR2 binding pocket occupancy; preclinical: KIF5B-RET Ba/F3 cells IC50 ~2 nM; in vivo LC-2/ad RET fusion+ xenograft tumor regression; LOXO-292 PATENT: WO2018071447 (Loxo Oncology; priority 2016); US10,040,786 (issued August 2018); VELOCITYEHS NULL: CAS 2097132-94-8 → null; NIOSH HD Category 1 absent; first selective RET inhibitor absent; VEGFR2 selectivity absent; RET V804M gatekeeper mutation coverage absent; KIF5B-RET/CCDC6-RET fusion absent; LIBRETTO-001 absent; 44F Loxo Oncology Stamford CT clinical scientist RET program 11yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY LIBRETTO-001 Trial Site Thoracic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Ave, New York NY 10065; MSK SELPERCATINIB CONTEXT: MSK enrolled patients in LIBRETTO-001 (NCT03157128; phase 1/2; 2017-onward); MSK thoracic oncology pharmacy prepares Retevmo: dispense 40 mg or 80 mg capsules; counsel on food interactions (take consistently with or without food); monitor LFTs per schedule (days 1, 8, 15, 22, then monthly × 6, then every 3 months); QTc monitoring per ECG schedule; DRUG INTERACTIONS: strong CYP3A4 inhibitors/inducers (selpercatinib is CYP3A4 substrate; dose adjustment required); acid-reducing agents (proton pump inhibitors reduce selpercatinib bioavailability ~92% → staggered dosing); RET TESTING AT MSK: RNA-based comprehensive tumor sequencing (MSK-IMPACT hybrid capture; 468-gene panel) or Archer FusionPlex liquid biopsy detect KIF5B-RET, CCDC6-RET, NCOA4-RET fusions; MSK-IMPACT also detects RET M918T, C634W point mutations; EHS INSIGHT NULL: CAS 2097132-94-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first selective RET inhibitor absent; KIF5B-RET fusion absent; LIBRETTO-001 ORR 68% absent; RET-mutant MTC ORR 73% absent; RTOR approval absent; NIOSH HD Cat 1 absent; 39M MSK New York NY thoracic oncology pharmacist selpercatinib 12yr).

Integrating Glyphward into Selpercatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selpercatinib CAS 2097132-94-8 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Loxo Oncology Stamford CT, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-FIFTH MECHANISM CLASS — FIRST SELECTIVE RET KINASE INHIBITOR EVER FDA APPROVED (NDA 213246 May 8 2020; RET IC50 ~0.92 nM; >50-fold VEGFR2 selectivity; KIF5B-RET/CCDC6-RET fusions; LIBRETTO-001 ORR 68% DOR 17.5 months OS 24.4 months; ORR 73% RET-mutant MTC; RTOR + Breakthrough Therapy; Eli Lilly/Loxo Oncology $8B) [5 pts]; Eli Lilly Indianapolis IN + Loxo Oncology Stamford CT + MSK New York NY [3 pts]; selective RET mechanism absent; KIF5B-RET absent; LIBRETTO-001 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selpercatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan selpercatinib with seventy-fifth-class first-selective-ret-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_fifth_class_first_selective_ret_kinase_inhibitor_ever_ret_ic50_0_92nm_50fold_vegfr2_selectivity_kif5b_ret_ccdc6_ret_fusion_libretto001_orr_68pct_dor_17_5mo_os_24_4mo_ret_mutant_mtc_orr_73pct_rtor_breakthrough_therapy_eli_lilly_loxo_oncology_8b_nda_213246"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_fifth_class,
    #                    first_selective_ret_inhibitor, ret_ic50_0_92nm,
    #                    vegfr2_selectivity_50fold, kif5b_ret_fusion,
    #                    libretto001_orr_68pct, rtor_approval

if __name__ == "__main__":
    r = asyncio.run(scan_selpercatinib("2097132-94-8", 0.00053))
    print(r)
    # {'hd_category': 1, 'seventy_fifth_class': True,
    #  'first_selective_ret_inhibitor': True, 'ret_ic50_0_92nm': True,
    #  'vegfr2_selectivity_50fold': True, 'kif5b_ret_fusion': True,
    #  'libretto001_orr_68pct': True, 'rtor_approval': True}